Status:
NOT_YET_RECRUITING
Post-market Prospective, Multicenter, Randomized and Single-blinded Clinical Investigation to Evaluate Whether Cardiac Re-Synchronization Therapy (CRT) Using Automatic Continuous Atrioventricular (AV) Delay Optimization is Superior to CRT With Conventional Biventricular Stimulation (BiV).
Lead Sponsor:
Antonio Rapacciuolo
Conditions:
Heart Failure
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
The goal of this randomized, multicenter prospective study is to demonstrate that the activation of biventricular pacing with fusion and AV optimization feature will increase the rate of CRT responder...
Detailed Description
Treatment of HFrEF with CRT. CRT is an established guideline-recommended treatment for patients who are refractory to optimized pharmacologic therapy, and have reduced ejection fraction and increased ...
Eligibility Criteria
Inclusion
- More than 18 years of age;
- Have signed the Informed Consent form.
- have been implanted with an Abbott CRT-D with the Sync-AV dynamic function under the current Class I or Class IIa ESC indications (2021 guidelines) for CRT implantation (including upgrades from single or dual chamber pacemakers or ICDs);
- Have to be in sinus rhythm at the Baseline visit and with Left Branch Block (LBBB) (2021 ESC/REVERSE):
- LVEF needs to be \<35% while under optimal medical treatment
- to be willing to meet all study requirements and have the ability to do participate to this study.
Exclusion
- Inclusion / Exclusion criteria: Inclusion criteria: To participate in this clinical study, patients must meet ALL of the following inclusion criteria:
- More than 18 years of age;
- Have signed the Informed Consent form.
- And have been implanted with an Abbott CRT-D with the Sync-AV dynamic function under the current Class I or Class IIa ESC indications (2021 guidelines) for CRT implantation (including upgrades from single or dual chamber pacemakers or ICDs);
- Have to be in sinus rhythm at the Baseline visit and with Left Branch Block (LBBB) (2021 ESC/REVERSE):
- LVEF needs to be \<35% while under optimal medical treatment
- In addition, patients need to be willing to meet all study requirements and have the ability to do participate to this study.
- Exclusion criteria: Patients who meet any of the following exclusion criteria are NOT eligible to participate in the clinical study:
- Having suffered a myocardial infarction or unstable angina in the 40 days prior to inclusion.
- Having undergone coronary revascularization (PTCA, Stent or CABG) in the 4 weeks prior to inclusion.
- Having suffered a Cerebrovascular Accident (CVA) or a Transient Ischemic Accident (TIA) in the 3 months prior to inclusion.
- NYHA Class IV.
- Having received a heart transplant or being waiting to receive it (status I classification);
- Suffering from primary valve disease requiring surgical intervention.
- Having long-lasting or permanent atrial fibrillation
- Showing inadequate transthoracic echocardiographic images which will not allow to establish cardiac output and LV volumes.
- Having a life expectancy \<12months.
- Being pregnant or planning to become pregnant during the clinical investigation.
- Inability to meet the monitoring schedule.
- Currently participating in any other clinical interventional research.
- Having a permanent high degree AV block
Key Trial Info
Start Date :
October 1 2023
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
October 30 2026
Estimated Enrollment :
722 Patients enrolled
Trial Details
Trial ID
NCT06044597
Start Date
October 1 2023
End Date
October 30 2026
Last Update
September 21 2023
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.